BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(SWOT20MY1647)
◆英語タイトル:BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1647
◆発行会社(リサーチ会社):GlobalData
◆発行日:2020年4月
◆ページ数:60
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

BioMarin Pharmaceutical Inc (BMRN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product category consists of multiple clinical and preclinical offerings. The company operates through its manufacturing facilities in Novato, California. It conducts its business operations in the US, Europe, Latin America, the Middle East and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc Key Recent Developments

Apr 21,2020 BioMarin appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations
Feb 26,2020 BioMarin announces fourth quarter and record full-year 2019 financial results
Feb 03,2020 BioMarin announces CFO succession
Dec 10,2019 Invitae announces program with BioMarin to expand access to genetic testing for Skeletal Dysplasias

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
BioMarin Pharmaceutical Inc – Key Facts
BioMarin Pharmaceutical Inc – Key Employees
BioMarin Pharmaceutical Inc – Key Employee Biographies
BioMarin Pharmaceutical Inc – Major Products and Services
BioMarin Pharmaceutical Inc – History
BioMarin Pharmaceutical Inc – Company Statement
BioMarin Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
BioMarin Pharmaceutical Inc – Business Description
Product Category: Aldurazyme
Overview
Performance
Product Category: Brineura
Overview
Performance
Product Category: Firdapse
Overview
Performance
Product Category: Kuvan
Overview
Performance
Product Category: Naglazyme
Overview
Performance
Product Category: Palynziq
Overview
Performance
Product Category: Vimizim
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
BioMarin Pharmaceutical Inc – Corporate Strategy
BioMarin Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
BioMarin Pharmaceutical Inc – Strengths
BioMarin Pharmaceutical Inc – Weaknesses
BioMarin Pharmaceutical Inc – Opportunities
BioMarin Pharmaceutical Inc – Threats
BioMarin Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 21, 2020: BioMarin appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations
Feb 26, 2020: BioMarin announces fourth quarter and record full-year 2019 financial results
Feb 03, 2020: BioMarin announces CFO succession
Dec 10, 2019: Invitae announces program with BioMarin to expand access to genetic testing for Skeletal Dysplasias
Oct 23, 2019: BioMarin announces third quarter 2019 financial results
Oct 07, 2019: BioMarin promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer
Aug 01, 2019: BioMarin announces second quarter 2019 Financial Results
Jul 09, 2019: BioMarin appoints pharmaceutical veteran and former J & J executive, Liz McKee Anderson, to Board of Directors
Apr 25, 2019: BioMarin announces first quarter 2019 financial results
Feb 21, 2019: BioMarin announces full year and fourth quarter 2018 results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
BioMarin Pharmaceutical Inc, Key Facts
BioMarin Pharmaceutical Inc, Key Employees
BioMarin Pharmaceutical Inc, Key Employee Biographies
BioMarin Pharmaceutical Inc, Major Products and Services
BioMarin Pharmaceutical Inc, History
BioMarin Pharmaceutical Inc, Subsidiaries
BioMarin Pharmaceutical Inc, Joint Venture
BioMarin Pharmaceutical Inc, Key Competitors
BioMarin Pharmaceutical Inc, Ratios based on current share price
BioMarin Pharmaceutical Inc, Annual Ratios
BioMarin Pharmaceutical Inc, Annual Ratios (Cont...1)
BioMarin Pharmaceutical Inc, Interim Ratios
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
BioMarin Pharmaceutical Inc, Performance Chart (2015 - 2019)
BioMarin Pharmaceutical Inc, Ratio Charts
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析(BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆